GFAP and early-onset autosomal dominant Alzheimer disease: Plasma biomarkers can measure by-products of non-specific neurodegeneration (NfL or GFAP) or specific neuropathologies like Alzheimer’s disease (Aβ 42/40 ratio, P-Tau181).